Announcements Trials
Browse Landscape

Phase

Phase NA 3

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Neoplasms 1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1Gastrointestinal Neoplasms 1

Interventions

pembrolizumab 593Cyclophosphamide 539Magnetic Resonance Spectroscopy 527Radiotherapy 506Specimen Handling 504Nivolumab 406Cisplatin 370Carboplatin 360Biopsy 306Blood Specimen Collection 296Radiosurgery 284Paclitaxel 276Surveys and Questionnaires 269Standard of Care 267Gemcitabine 266fludarabine 261Dexamethasone 258Drug Therapy 256Bevacizumab 248venetoclax 247Oxaliplatin 206Rituximab 197Capecitabine 194Radiation 190Fluorouracil 186Ipilimumab 183durvalumab 181Doxorubicin 174atezolizumab 172Etoposide 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Glutamyl Aminopeptidase × 1 year × Clear all
NCT05415527 2026-01-29

OPTIMOVA

Institut Bergonié

Phase NA Active not recruiting
25 enrolled
Gynecologic

Ovarian Neoplasms

NCT05649943 2025-09-03

APPROACH

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase NA Recruiting
566 enrolled
Genitourinary

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

NCT05441163 2025-06-24

ProActIF-01

Institut Curie

Phase NA Recruiting
50 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡